BioCentury | Apr 29, 2020
Emerging Company Profile

Bugworks: breaking the U.S.-centric antimicrobial mold

...Once they enter the bacteria, the Gyrox antibiotics disrupt DNA replication by inhibiting topoisomerase and DNA gyrase...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant

...DNA gyrase could treat drug-resistant Staphylococcus aureus infections. In vitro , the compound inhibited S. aureus DNA gyrase...
...identified through a screen of synthetic small molecules previously reported to inhibit Gram-positive bacteria. TARGET/MARKER/PATHWAY: DNA gyrase...
...2, 2019 doi:10.1016/j.chembiol.2019.06.002 CONTACT: Justin Nodwell, University of Toronto, Toronto, Ontario email: justin.nodwell@utoronto.ca Claire Quang University of Toronto DNA gyrase Staphylococcus...
BioCentury | Jun 20, 2019
Company News

Spero's TB program first licensing deal for Gates Medical Research Institute

...advance the compound for TB. Financial terms were not disclosed. The biotech acquired SPR720, a DNA gyrase...
...resistance mechanisms (see "Bug Money" ). Karen Tkach Tuzman, Associate Editor Bill & Melinda Gates Foundation Spero Therapeutics Inc. DNA gyrase...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Infectious disease

...infection In vitro , cell culture, mouse, rat and dog studies identified a spiropyrimidinetrione-based bacterial DNA gyrase...
...assays of analogs of a previously reported spiropyrimidinetrione yielded a compound that inhibited S. aureus DNA gyrase...
...of systemic MRSA or MSSA infection, the compound prolonged survival with greater potency than the DNA gyrase...
BioCentury | Sep 28, 2018
Financial News

Entasis raises $75M in IPO

...The Drugs for Neglected Diseases initiative will fund the trial. Zoliflodacin is an oral benzisoxazole DNA gyrase...
BioCentury | Sep 26, 2018
Financial News

Entasis dips in first trading day after $75M IPO

...The Drugs for Neglected Diseases initiative will fund the trial. Zoliflodacin is an oral benzisoxazole DNA gyrase...
BioCentury | Aug 31, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

...investor in its $40 million series A round. Entasis' zoliflodacin (ETX0914) is an oral benzisoxazole DNA gyrase...
BioCentury | Aug 17, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

...investor in its $40 million series A round. Entasis' zoliflodacin (ETX0914) is an oral benzisoxazole DNA gyrase...
BioCentury | Apr 6, 2018
Clinical News

Aradigm's Linhaliq under EMA review for lung infection

...2013 deal. Linhaliq is a dual-release product consisting of a liposomal-encapsulated form of ciprofloxacin, a DNA gyrase...
...Barcelona, Spain Product: Linhaliq liposomal ciprofloxacin Business: Infectious disease Jennie Walters Linhaliq, liposomal ciprofloxacin (ARD-3150, pulmaquin) Aradigm Corp. Grifols S.A. DNA gyrase...
BioCentury | Apr 5, 2018
Company News

Aradigm's Linhaliq under EMA review for lung infection

...2013 deal. Linhaliq is a dual-release product consisting of a liposomal-encapsulated form of ciprofloxacin, a DNA gyrase...
Items per page:
1 - 10 of 195